Selskabets formål er at drive fabrikation af og handel med medicinalvarer til human eller veterinær brug, finkemikalier, kosmetik, forskning og udvikling samt hermed beslægtet virksomhed enten direkte eller ved anbringelse af kapital i selskaber med ligende formål samt at virke som repræsentant eller alliancepartner for danske og udenlandske virksomheder inden for sådanne forretningsområder.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 1.6 mia. | 829 mio. | 3.2 mia. | 162.5 mio. | 547 | |
CVR: 61094628
Secondary names: AXELLIA PHARMACEUTICALS ApS
5 properties
Upgrade to Pro to see addresses, building data and ownership details
Companies in the same industry and area
CVR 44654482
CVR 45239128
CVR 35442723
CVR 35435212
CVR 39014149
Compared to 24 companies in Fremstilling af farmaceutiske råvarer
Comparison is based on industry median values
Xellia Pharmaceuticals ApS has experienced a significant turnaround in financial health from 2023 to 2024, achieving a revenue of 1.6 billion DKK and a profit of 829 million DKK, a stark contrast to the previous year's loss of 2.4 billion DKK. However, the company's equity remains low at 162 million DKK, following a decline from 2.6 billion DKK in 2020, indicating ongoing concerns about its financial stability. The revenue trend shows a decline from 2022's peak of 2.2 billion DKK, highlighting potential challenges in maintaining market position within the pharmaceutical raw materials industry. Overall, while profitability has improved, the equity position and historical losses raise concerns about long-term sustainability.
AI-generated summary
companydata.dk